Australia markets open in 3 hours 51 minutes

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0940-0.0030 (-3.09%)
At close: 01:43PM AEST
Full screen
Previous close0.0970
Open0.0910
Bid0.0870 x 10000000
Ask0.0940 x 249000000
Day's range0.0870 - 0.0950
52-week range0.0870 - 0.1850
Volume460,347
Avg. volume113,120
Market cap9.078M
Beta (5Y monthly)0.44
PE ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings date28 Aug 2024 - 01 Sept 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Genetic Technologies Expands Operational Capacity in North America

    Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory, Gene by GeneCHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assess

  • GlobeNewswire

    GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

    MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take

  • GlobeNewswire

    GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

    MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30, assesses a woman’s risk of cancer due to hereditary, inclu